Novartis AG is 206.5x more valuable than UroGen Pharma Ltd. by market capitalization ($283.13 B vs $1.37 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | URGN | NVS |
|---|---|---|
| Market cap | $1.37 B | $283.13 B |
| US-listed rank | #2404 | #47 |
| Revenue (latest FY) | $109.79M | - |
| Net income (latest FY) | -$153.49M | - |
| Net margin | -139.8% | - |
| SEC filings | 549 | 947 |
Novartis AG is 206.5x more valuable than UroGen Pharma Ltd. by market capitalization ($283.13 B vs $1.37 B).
Full pages: UroGen Pharma Ltd. and Novartis AG, or browse the full rankings.